Business
Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
Everest Medicines (HKEX: 1952.HK) today announced that its licensing partner, NovaBridge Biopharma (NASDAQ: NBP, "NovaBridge"), together with its subsidiary Visara, Inc. ("Visara"), reported positive topline results from the Phase 2a study of VIS-101, a purpose-designed tetravalent, dual VEGF-A X ANG-2 inhibitor in development for retinal vascular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Topline results sho
About this update from Everest Medicines Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"VIS-101 demonstrated mean BVCA improvements of >10 ETDRS letters and median CST reductions of 100-150 mm","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Potentially best-in-class durability with a favorable safety profile and no dose-limiting toxicity","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2b dose-determining study expected to begin in H2 2026; global Phase 3 program expected to begin in 2027","length":110,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":539,"olType":false},{"type":"text","content":"SHANGHAI, March 13, 2026 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK) today announced that its licensing partner, NovaBridge Biopharma (NASDAQ: NBP, "NovaBridge"), together with its subsidiary Visara, Inc. ("Visara"), reported positive topline results from the Phase 2a study of VIS-101, a purpose-designed tetravalent, dual VEGF-A X ANG-2 inhibitor in development for retinal vascular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Topline results show that VIS-101 produced rapid, robust and durable treatment responses in wet AMD, with potential best-in-class durability and a favorable safety profile. Wet AMD affects more than 20 million people globally[1].","length":776,"tagName":"p"},{"type":"text","content":"Topline Data:","length":13,"tagName":"p"},{"type":"text","content":"VIS-101 produced rapid and robust efficacy, and durable treatment responses with both 3 mg and 6 mg dose cohorts:","length":113,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Mean improvement in Best Corrected Visual Acuity (BCVA) of >10 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Median central subfield thickness (CST) reduction of 100-150 mm","length":63,"tagName":"p"}]},{"val":[{"type":"text","c...